Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
Objective The objective of this study is to elucidate the effect of anagliptin on glucose/lipid metabolism and renoprotection in patients with type 2 diabetic nephropathy.Methods Twenty-five patients with type 2 diabetic nephropathy received anagliptin 200 mg/day for 24 weeks, and 20 patients who we...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2017-07-01
|
| Series: | BMJ Open Diabetes Research & Care |
| Online Access: | https://drc.bmj.com/content/5/1/e000391.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849730152308670464 |
|---|---|
| author | Daisuke Koya Mizue Fujii Munehiro Kitada Shin-ichi Tsuda Kazunori Konishi Ai Takeda-Watanabe Keizo Kanasaki Makoto Nishizawa Atsushi Nakagawa |
| author_facet | Daisuke Koya Mizue Fujii Munehiro Kitada Shin-ichi Tsuda Kazunori Konishi Ai Takeda-Watanabe Keizo Kanasaki Makoto Nishizawa Atsushi Nakagawa |
| author_sort | Daisuke Koya |
| collection | DOAJ |
| description | Objective The objective of this study is to elucidate the effect of anagliptin on glucose/lipid metabolism and renoprotection in patients with type 2 diabetic nephropathy.Methods Twenty-five patients with type 2 diabetic nephropathy received anagliptin 200 mg/day for 24 weeks, and 20 patients who were switched to anagliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors were analyzed regarding primary and secondary endpoints. The primary endpoint was change in hemoglobin A1c (HbA1c) during treatment with anagliptin. Additionally, we evaluated changes in lipid data (low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglyceride), blood pressure (BP), urinary albumin to creatinine ratio (UACR), liver-type fatty acid-binding protein to creatinine ratio (ULFABP) and renal function (estimated glomerular filtration rate and serum cystatin C) as secondary endpoints.Results After switching to anagliptin from other DPP-4 inhibitors, the levels of HbA1c in the 20 participants showed no significant change, 7.5%±1.2% at 24 weeks compared with 7.3%±0.9% at baseline. The levels of the log10-transformed UACR were significantly reduced from 1.95±0.51 mg/g creatinine (Cr) at baseline to 1.76±0.53 mg/g Cr at 24 weeks after anagliptin treatment (p<0.01). The percentage change in the UACR (Δ%UACR) from baseline to 24 weeks was also significantly lower by −10.6% (p<0.001). Lipid data, systolic BP and renal function were not changed during anagliptin treatment. Additionally, ULFABP in eight participants, who had ≥5 µg/g Cr at baseline, was significantly decreased from baseline (8.5±2.8 µg/g Cr) to 24 weeks (3.1±1.7 µg/g Cr, p<0.01) after anagliptin treatment, and the percentage change in the ULFABP during anagliptin treatment was −58.1% (p<0.001).Conclusions Anagliptin induced no significant change in HbA1c, lipid data, systolic BP and renal function. However, anagliptin reduced the UACR and ULFABP, although without a corresponding change in HbA1c, indicating direct action of anagliptin on renoprotection in patients with type 2 diabetic nephropathy. |
| format | Article |
| id | doaj-art-c36c819b9c834110a059032e429d810f |
| institution | DOAJ |
| issn | 2052-4897 |
| language | English |
| publishDate | 2017-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Diabetes Research & Care |
| spelling | doaj-art-c36c819b9c834110a059032e429d810f2025-08-20T03:08:59ZengBMJ Publishing GroupBMJ Open Diabetes Research & Care2052-48972017-07-015110.1136/bmjdrc-2017-000391Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent mannerDaisuke Koya0Mizue Fujii1Munehiro Kitada2Shin-ichi Tsuda3Kazunori Konishi4Ai Takeda-Watanabe5Keizo Kanasaki6Makoto Nishizawa7Atsushi Nakagawa81 Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan1 Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan1 Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan1 Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan1 Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan1 Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, JapanDepartment of Internal Medicine 1, Faculty of Medicine, Shimane University, Shimane, Japan1 Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan1 Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, JapanObjective The objective of this study is to elucidate the effect of anagliptin on glucose/lipid metabolism and renoprotection in patients with type 2 diabetic nephropathy.Methods Twenty-five patients with type 2 diabetic nephropathy received anagliptin 200 mg/day for 24 weeks, and 20 patients who were switched to anagliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors were analyzed regarding primary and secondary endpoints. The primary endpoint was change in hemoglobin A1c (HbA1c) during treatment with anagliptin. Additionally, we evaluated changes in lipid data (low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglyceride), blood pressure (BP), urinary albumin to creatinine ratio (UACR), liver-type fatty acid-binding protein to creatinine ratio (ULFABP) and renal function (estimated glomerular filtration rate and serum cystatin C) as secondary endpoints.Results After switching to anagliptin from other DPP-4 inhibitors, the levels of HbA1c in the 20 participants showed no significant change, 7.5%±1.2% at 24 weeks compared with 7.3%±0.9% at baseline. The levels of the log10-transformed UACR were significantly reduced from 1.95±0.51 mg/g creatinine (Cr) at baseline to 1.76±0.53 mg/g Cr at 24 weeks after anagliptin treatment (p<0.01). The percentage change in the UACR (Δ%UACR) from baseline to 24 weeks was also significantly lower by −10.6% (p<0.001). Lipid data, systolic BP and renal function were not changed during anagliptin treatment. Additionally, ULFABP in eight participants, who had ≥5 µg/g Cr at baseline, was significantly decreased from baseline (8.5±2.8 µg/g Cr) to 24 weeks (3.1±1.7 µg/g Cr, p<0.01) after anagliptin treatment, and the percentage change in the ULFABP during anagliptin treatment was −58.1% (p<0.001).Conclusions Anagliptin induced no significant change in HbA1c, lipid data, systolic BP and renal function. However, anagliptin reduced the UACR and ULFABP, although without a corresponding change in HbA1c, indicating direct action of anagliptin on renoprotection in patients with type 2 diabetic nephropathy.https://drc.bmj.com/content/5/1/e000391.full |
| spellingShingle | Daisuke Koya Mizue Fujii Munehiro Kitada Shin-ichi Tsuda Kazunori Konishi Ai Takeda-Watanabe Keizo Kanasaki Makoto Nishizawa Atsushi Nakagawa Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner BMJ Open Diabetes Research & Care |
| title | Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_full | Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_fullStr | Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_full_unstemmed | Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_short | Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_sort | anagliptin ameliorates albuminuria and urinary liver type fatty acid binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose lowering independent manner |
| url | https://drc.bmj.com/content/5/1/e000391.full |
| work_keys_str_mv | AT daisukekoya anagliptinamelioratesalbuminuriaandurinarylivertypefattyacidbindingproteinexcretioninpatientswithtype2diabeteswithnephropathyinaglucoseloweringindependentmanner AT mizuefujii anagliptinamelioratesalbuminuriaandurinarylivertypefattyacidbindingproteinexcretioninpatientswithtype2diabeteswithnephropathyinaglucoseloweringindependentmanner AT munehirokitada anagliptinamelioratesalbuminuriaandurinarylivertypefattyacidbindingproteinexcretioninpatientswithtype2diabeteswithnephropathyinaglucoseloweringindependentmanner AT shinichitsuda anagliptinamelioratesalbuminuriaandurinarylivertypefattyacidbindingproteinexcretioninpatientswithtype2diabeteswithnephropathyinaglucoseloweringindependentmanner AT kazunorikonishi anagliptinamelioratesalbuminuriaandurinarylivertypefattyacidbindingproteinexcretioninpatientswithtype2diabeteswithnephropathyinaglucoseloweringindependentmanner AT aitakedawatanabe anagliptinamelioratesalbuminuriaandurinarylivertypefattyacidbindingproteinexcretioninpatientswithtype2diabeteswithnephropathyinaglucoseloweringindependentmanner AT keizokanasaki anagliptinamelioratesalbuminuriaandurinarylivertypefattyacidbindingproteinexcretioninpatientswithtype2diabeteswithnephropathyinaglucoseloweringindependentmanner AT makotonishizawa anagliptinamelioratesalbuminuriaandurinarylivertypefattyacidbindingproteinexcretioninpatientswithtype2diabeteswithnephropathyinaglucoseloweringindependentmanner AT atsushinakagawa anagliptinamelioratesalbuminuriaandurinarylivertypefattyacidbindingproteinexcretioninpatientswithtype2diabeteswithnephropathyinaglucoseloweringindependentmanner |